- Home
- RNA vs CPRX Comparison
RNA vs CPRX Comparison
Compare RNA & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- CPRX
- Stock Information
- Founded
- RNA 2012
- CPRX 2002
- Country
- RNA United States
- CPRX United States
- Employees
- RNA N/A
- CPRX N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- CPRX Biotechnology: Pharmaceutical Preparations
- Sector
- RNA Health Care
- CPRX Health Care
- Exchange
- RNA Nasdaq
- CPRX Nasdaq
- Market Cap
- RNA 4.4B
- CPRX 2.9B
- IPO Year
- RNA 2020
- CPRX 2006
- Fundamental
- Price
- RNA $29.31
- CPRX $22.48
- Analyst Decision
- RNA Strong Buy
- CPRX Strong Buy
- Analyst Count
- RNA 14
- CPRX 6
- Target Price
- RNA $68.00
- CPRX $32.83
- AVG Volume (30 Days)
- RNA 1.4M
- CPRX 1.2M
- Earning Date
- RNA 08-08-2025
- CPRX 08-06-2025
- Dividend Yield
- RNA N/A
- CPRX N/A
- EPS Growth
- RNA N/A
- CPRX 178.13
- EPS
- RNA N/A
- CPRX 1.57
- Revenue
- RNA $8,927,000.00
- CPRX $534,645,999.00
- Revenue This Year
- RNA N/A
- CPRX $16.37
- Revenue Next Year
- RNA $155.06
- CPRX $8.80
- P/E Ratio
- RNA N/A
- CPRX $14.32
- Revenue Growth
- RNA N/A
- CPRX 29.97
- 52 Week Low
- RNA $21.51
- CPRX $14.75
- 52 Week High
- RNA $56.00
- CPRX $26.58
- Technical
- Relative Strength Index (RSI)
- RNA 42.04
- CPRX 34.18
- Support Level
- RNA $31.59
- CPRX $23.25
- Resistance Level
- RNA $38.00
- CPRX $23.91
- Average True Range (ATR)
- RNA 2.01
- CPRX 0.77
- MACD
- RNA -0.59
- CPRX -0.37
- Stochastic Oscillator
- RNA 9.67
- CPRX 4.75
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).